Sage Therapeutics’ clinical-trial blowup should remind biotech investors that even the healthiest-looking stock is at risk.
Heard on the Street | Safety and Biotech Investing Don’t Mix |
|
| Sage Therapeutics’ clinical-trial blowup should remind biotech investors that even the healthiest-looking stock is at risk. |
| | | |
|
|
|
Unsubscribe |